🚨 Arch Biopartners announced that St. Michael’s Hospital @unityhealthto.bsky.social received ethics approval to join the Phase II CS-AKI trial evaluating LSALT peptide.

🏥 4th Canadian site, 9th globally.

🔗 Read more (and share): www.archbiopartners.com/arch-biopart...

#LSALTpeptide #AKI #CSAKI

🚨 Arch Biopartners has announced that the @fraserhealth.ca Research Ethics Board has approved Royal Columbian Hospital to join its Phase II trial of LSALT peptide to prevent CS-AKI.

📖 Latest News at www.archbiopartners.com/investor-hub/

#AKI #CSAKI #KidneyCare #NephSky

🚨 Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD).

🔬 Full News Release: archbiopartners.com/investor-hub/press-releases/

#KidneyCare #CKD #NephSky #ArchBiopartners

📊 A 2022 study in Kidney International (doi.org/10.1016/j.kint.2022.02.033) showed consistent AKI incidence and outcomes across Canada, Denmark, and the UK using harmonized KDIGO definitions.

Supports the need for targeted kidney therapies.

🔬 archbiopartners.com/our-science

#AKI #CSAKI #NephSky

Arch Biopartners’ CS-AKI Phase II clinical trial is now active at Toronto General Hospital, ranked Canada's #1 and #3 globally.

First patient dosed in the trial at this leading cardiac research hospital.

🔗 dub.sh/first-patien...

#ArchBiopartners #CSAKI #AKI #LSALTpeptide #clinicaltrials #ArchNews

🚨 Arch Biopartners now has two lead drug candidates in active Phase II trials:

🔹 Cilastatin: in the PONTIAK trial for drug-toxin-related AKI, now open for recruitment
🔹 LSALT peptide: cardiac surgery-associated AKI

🔗 archbiopartners.com/investor-hub...

#AKI #Cilastatin #LSALTpeptide #ArchNews

📢 Arch Biopartners’ May 2025 Corporate Presentation –Covers the CS-AKI and PONTiAK Phase II trials targeting inflammation- and toxin-related AKI.
📽️ Download the presentation and subscribe for updates at the Arch Investor Hub: www.archbiopartners.com/investor-hub/
#ArchBiopartners #CSAKI #InvestorFAQ